S100A10 expression was significantly upregulated in cervical and endocervical cancers, colon adenocarcinoma, glioblastoma multiforme, kidney renal clear cell carcinoma, kidney renal papillary carcinoma, acute myeloid leukemia, brain lower grade glioma, liver hepatocellular carcinoma, pancreatic adenocarcinoma, rectum adenocarcinoma, stomach adenocarcinoma, and testicular germ cell tumors. Here, S100A10 is linked to gastric adenocarcinoma.